Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3

• Claus Niederau ,

  * E-mail: c.niederau@kk-ob.de

  Affiliation Clinic for Internal Medicine, St. Josef Hospital, Oberhausen, Germany

  ⨯
• Stefan Mauss,

  Affiliation Center for HIV and Hepatogastroenterology, Duesseldorf, Germany

  ⨯
• Andreas Schober,

  Affiliation Center of Gastroenterology, Goettingen, Germany

  ⨯
• Albrecht Stoehr,

  Affiliation ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany

  ⨯
• Tim Zimmermann,

  Affiliation 1st Medical Clinic, Dept. Gastroenterology and Hepatology, Johannes Gutenberg University of Mainz, Mainz, Germany

  ⨯
• Michael Waizmann,

  Affiliation Medcenter Leipzig, Leipzig, Germany

  ⨯
• Gero Moog,

  Affiliation Center of Gastroenterology, Kassel, Germany

  ⨯
• Stefan Pape,

  Affiliation Center of Gastroenterology, Paderborn, Germany

  ⨯
• Bernd Weber,

  Affiliation Competence Center for Addiction, Praxiszentrum Friedrichsplatz, Kassel, Germany

  ⨯
• Konrad Isernhagen,

  Affiliation Practice for general medicine, Koeln, Germany

  ⨯
• Petra Sandow,

  Affiliation General Practice, Berlin, Germany

  ⨯
• Bernd Bokemeyer,

  Affiliation Gastroenterology Practice, Minden, Germany

  ⨯
• Ulrich Alshuth,

  Affiliation Virology, Roche Pharma AG, Grenzach-Wyhlen, Germany

  ⨯
• Hermann Steffens,

  Affiliation Practice for internal Medicine, Berlin, Germany

  ⨯
• Dietrich Hüppe

  Affiliation Center of Gastroenterology, Herne, Germany

  ⨯